Theratechnologies (TH)

Quick facts

Marketed products

• Placebo-Control
  Placebo-Control is not an active pharmaceutical agent but rather an inert control substance used in clinical trials to establish baseline efficacy and safety comparisons.
• Egrifta · Immunology
  Egrifta works by mimicking the action of growth hormone-releasing hormone to stimulate the release of growth hormone.

Phase 3 pipeline

• Placebo for Tesamorelin · Clinical Trial Control
  A placebo control contains no active pharmaceutical ingredient and produces no pharmacological effect.
• TH9507 · Endocrinology / Infectious Disease
  TH9507 is a recombinant human growth hormone (hGH) analog designed to stimulate growth and metabolic function in patients with growth hormone deficiency or wasting conditions.

Phase 2 pipeline

• HIV Anti-retroviral Background Therapy · Infectious Disease
  Inhibits HIV replication by targeting the CCR5 receptor
• On ibalizumab treatment

Phase 1 pipeline

• TH1902

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Theratechnologies portfolio CI brief
• Theratechnologies pipeline updates RSS